Yamada C, Yamada Y, Tsukiyama K, Yamada K, Udagawa N, Takahashi N, et al
The 2014 NICHD multicenter RCT of 750 women established letrozole as first-line medical ovulation induction for PCOS, with cumulative live-birth rates of 27.5% versus 19.1% for clomiphene (Legro et al
It is in the hands of prescribing clinicians and patients to develop a comprehensive, whole-patient plan
A., Hollander, P., Klein, S., Niswender, K
In participants with obesity or overweight, withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and augmented initial weight reduction [75]